Personalized medicine for HLA-associated drug-hypersensitivity reactions

Personalized Medicine

Volumn 7, Issue 5, 2010, Pages 495-516

  Bharadwaj, Mandvi ^a   Illing, Patricia ^a   Kostenko, Lyudmila ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

drug hypersensitivity; HLA; personalized treatment; Tcells

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; ALLOPURINOL; AMPICILLIN; AUROTHIOMALATE; CARBAMAZEPINE; CLOAZARIL; CLOZAPINE; FEPRAZONE; FLUCLOXACILLIN; HLA ANTIGEN; HYDRALAZINE; LEVAMISOLE; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PENICILLAMINE; PHENYTOIN; SULFAMETHOXAZOLE; SULFONAMIDE; UNCLASSIFIED DRUG; XIMELAGATRAN;

AGRANULOCYTOSIS; ALLOTYPE; ANAPHYLAXIS; ASTHMA; CLINICAL DECISION MAKING; DNA DETERMINATION; DRESS SYNDROME; DRUG ERUPTION; DRUG HYPERSENSITIVITY; FOOD AND DRUG ADMINISTRATION; HEPATITIS; HEREDITY; HLA SYSTEM; HLA TYPING; HUMAN; IMMUNOTHERAPY; LIVER INJURY; MEDICINE; MOLECULAR MECHANICS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

EID: 77957563035     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.10.46     Document Type: Review

References (147)

1. Johnson JA, Bootman JL: Drug-related morbidity and mortality. A cost-of-illness model. Arch. Intern. Med. 155(18), 1949-1956 (1995).
2. Pichler WJ: Delayed drug hypersensitivity reactions. Ann. Intern. Med. 139(8), 683-693 (2003).
3. Hunziker T, Bruppacher R, Kuenzi UP et al.: Classification of ADRs: a proposal for harmonization and differentiation based on the experience of the comprehensive hospital drug monitoring Bern/St. Gallen, 1974-1993. Pharmacoepidemiol. Drug Saf. 11(2), 159-163 (2002). (Pubitemid 34464337)
4. Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK: Immunological principles of adverse drug reactions - the initiation and propagation of immune responses elicited by drug treatment. Drug Saf. 23(6), 483-507 (2000). (Pubitemid 32001512)
5. Horton R, Wilming L, Rand V et al.: Gene map of the extended human MHC. Nat. Rev. Genet. 5(12), 889-899 (2004). (Pubitemid 39564252)
6. Robinson J: The IMGT/HLA database. Nucleic Acids Res. 37, D1013-D1017 (2009).
7. Robinson J: IMGT/HLA database - a sequence database for the human major histocompatibility complex. Tissue Antigens 55(3), 280-287 (2000). (Pubitemid 30150951)
8. Hulsmeyer M, Fiorillo MT, Bettosini F et al.: Dual HLA-B27 subtype-dependent conformation of a self-peptide. J. Exp. Med. 199(2), 271-281 (2004). (Pubitemid 38139247)
9. Archbold JK, Macdonald WA, Gras S et al.: Natural micropolymorphism in human leukocyte antigens provides a basis for genetic control of antigen recognition. J. Exp. Med. 206(1), 209-219 (2009). •• Elucidates how HLA polymorphisms can affect the peptide-MHC landscape and influence T-cell receptor recognition thereby finetuning the T-cell responses.
10. Parham P, Ohta T: Population biology of antigen presentation by MHC class I molecules. Science 272(5258), 67-74 (1996). (Pubitemid 26110756)
11. Altfeld M, Addo MA, Rosenberg ES et al.: Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 17(18), 2581-2591 (2003). (Pubitemid 38402336)
12. Hill AV, Allsopp CE, Kwiatkowski D et al.: Common west African HLA antigens are associated with protection from severe malaria. Nature 352(6336), 595-600 (1991). (Pubitemid 21912384)
13. Hetherington S, Hughes AR, Mosteller M et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359(9312), 1121-1122 (2002). (Pubitemid 34270738)
14. *5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reversetranscriptase inhibitor abacavir. Lancet 359(9308), 727-732 (2002). (Pubitemid 34215071)
15. *5701 and a haplotypic Hsp70-Hom variant. Proc. Natl Acad. Sci. USA 101(12), 4180-4185 (2004). (Pubitemid 38405903)
16. *5801 and allopurinol-severe cutaneous adverse reactionsin the Han Chinese population.
17. *5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genomomics 19(9), 704-709 (2009).
18. Kaniwa N, Saito Y, Aihara M et al.: HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9(11), 1617-1622 (2008).
19. *1502 in the Han Chinese population.
20. *1502 in the Han Chinese population is isolated to Stevens-Johnson Syndrome/toxic epidermal necrolysis, and does not extend to the phe no typically different hypersensitivities maculopapular exanthema and hypersensitivity syndrome.
21. *1502 allele in Thai population. Epilepsia 49(12), 2087-2091 (2008).
22. Pichler W, Yawalkar N, Schmid S, Helbling A: Pathogenesis of drug-induced exanthems. Allergy 57(10), 884-893 (2002). •• Provides an overview on the distinct functions of T cells in three drug-induced skin reactions: maculopapular exanthema, bullous and pustular skin reactions. The review also provides mechanistic models for the covalent and noncovalent association of the drug with the MHC-peptide complex.
23. Arroyo S, de la Morena A: Life-threatening adverse events of antiepileptic drugs. Epilepsy Res. 47 (1-2), 155-174 (2001). (Pubitemid 32973656)
24. Hetherington S, McGuirk S, Powell G et al.: Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin. Ther. 23(10), 1603-1614 (2001). (Pubitemid 33063588)
25. Phillips EJ, Sandra RS, Sullivan NH, John RK: Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 16(16), 2223-2225 (2002).
26. Nassif A, Bensussan A, Dorothee G et al.: Drug specific cytotoxic T cells in the skin lesions of a patient with toxic epidermal necrolysis. J. Invest. Dermatol. 118(4), 728-733 (2002). (Pubitemid 34309997)
27. Hari Y, Frutig-Schnyder K, Hurni M et al.: T cell involvement in cutaneous drug eruptions. Clin. Exp. Allergy 31(9), 1398-1408 (2001). (Pubitemid 32823877)
28. Le Cleach L, Delaire S, Boumsell L et al.: Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin. Exp. Allergy 119(1), 225-230 (2000). (Pubitemid 30064614)
29. Nassif A, Bensussan A, Boumsell L et al.: Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. 114(5), 1209-1215 (2004). (Pubitemid 39469167)
30. Faletto MB, Miller WH, Garvey EP, St Clair MH, Daluge SM, Good SS: Unique intracellular activation of the potent antihuman immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. 41(5), 1099-1107 (1997).
31. Easterbrook PJ, Waters A, Murad S et al.: Epidemiological risk factors for hypersensitivity reactions to abacavir. HIV Med. 4(4), 321-324 (2003). (Pubitemid 37304372)
32. Phillips EJ, Wong GA, Kaul R et al.: Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 19(9), 979-981 (2005). (Pubitemid 40834943)
33. *5701 screening to prevent abacavir hypersensitivity reaction.
34. *5701 and abacavir hypersensitivity syndrome. (Pubitemid 351784513)
35. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort study. Clin. Infect. Dis. 43(1), 99-102 (2006). (Pubitemid 43939082)
36. *5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J. Acquir. Immune Defic. Syndr. 45(1), 1-3 (2007). (Pubitemid 46684436)
37. Colombo S, Rauch A, Rotger M et al.: The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J. Infect. Dis. 198(6), 864-867 (2008).
38. Hughes AR, Mosteller M, Bansal AT et al.: Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5(2), 203-211 (2004). (Pubitemid 38351278)
39. McLean MJ, Macdonald RL: Carbamazepine and 10, 11-epoxycarbamazepine produce use-dependent and voltage-dependent limitation of rapidly firing action-potentials of mouse central neurons in cell culture J. Pharmacol. Exp. Ther. 238(2), 727-738 (1986). (Pubitemid 16039621)
40. Lang DG, Wang CM, Cooper BR: Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J. Pharmacol. Exp. Ther. 266(2), 829-835 (1993).
41. Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs. N. Engl. J. Med. 331(19), 1272-1285 (1994). (Pubitemid 24333193)
42. Kamaliah MD, Zainal D, Mokhtar N, Nazmi N: Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in northeastern Malaysia. Int. J. Dermatol. 37(7), 520-523 (1998). (Pubitemid 28329047)
43. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R: Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. study group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 353(9171), 2190-2194 (1999). (Pubitemid 29295251)
44. *1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48(5), 1015-1018 (2007). (Pubitemid 46763406)
45. Alfirevic A, Chadwick DW, Park BK, Pirmohamed M: Lack of association between serious carbamazepine hypersensitivity reactions and HLA-B in Caucasians. Br. J. Clin. Pharmacol. 59(5), 641-641 (2005).
46. Lonjou C, Thomas L, Borot N et al.: A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J. 6(4), 265-268 (2006). (Pubitemid 44137953)
47. + channels. Mol. Pharmacol. 54(4), 712-721 (1998).
48. + T-cell clones from patients with carbamazepine hypersensitivity. J. Allergy Clin. Immunol. 119(4), 973-981 (2007). • In vitro characterization of carbamazepine reactive T-cell subsets. (Pubitemid 46527813)
49. Naisbitt DJ, Britschgi M, Wong G et al.: Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol. Pharmacol. 63(3), 732-741 (2003). (Pubitemid 36297347)
50. Wu Y, Sanderson JP, Farrell J et al.: Activation of T cells by carbamazepine and carbamazepine metabolites. J. Allergy Clin. Immunol. 118(1), 233-241 (2006). • Characterizes the T-cell response to carbamazepine and demonstrates that carbamazepine and its metabolites do not require antigen processing and immune cell metabolism but are presented to T cells rapidly via a direct interaction with MHC and specific T-cell receptors. (Pubitemid 43964854)
51. Massey V, Komai H, Palmer G, Elion GB: On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo [3, 4-d]pyrimidines. J. Biol. Chem. 245(11), 2837-2844 (1970).
52. Arellano F, Sacristan JA: Allopurinol hypersensitivity syndrome - a review. Ann. Pharmacother. 27(3), 337-343 (1993).
53. Lonjou C, Borot N, Sekula P et al.: A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomomics 18(2), 99-107 (2008).
54. *5801: a rapid and sensitive genotyping assays to lower the risk of the allopurinol induced SCAR. Clin. Chem. 54(6), A163-A163 (2008).
55. Ozkaya-Bayazit E, Akar U: Fixed drug eruption induced by trimethoprimsulfamethoxazole: evidence for a link to HLA-A30-B13-Cw 6 haplotype. J. Am. Acad. Dermatol. 45(5), 712-717 (2001). (Pubitemid 33032568)
56. + T cells during the evolution of fixed drug eruption. Br. J. Dermatol. 158(6), 1230-1238 (2008). (Pubitemid 351692861)
57. Pellicano R, Lomuto M, Ciavarella G, Di Giorgio G, Gasparini P: Fixed drug eruptions with feprazone are linked to HLA-B22. J. Am. Acad. Dermatol. 36(5), 782-784 (1997). (Pubitemid 27215370)
58. Russmann S, Kaye JA, Jick SS, Jick H: Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br. J. Clin. Pharmacol. 60(1), 76-82 (2005). (Pubitemid 40942784)
59. Fairley CK, McNeil JJ, Desmond P et al.: Risk-factors for development of flucloxacillin associated jaundice BMJ 306(6872), 233-235 (1993). (Pubitemid 23027961)
60. *5701 to be the main common genetic risk factor for flucloxacillin-induced liver injury and also provided suggestive evidence for additional contributions from other loci.
61. Maria VAJ, Victorino RMM: Diagnostic value of specific T-cell reactivity to drugs in 95 cases of drug induced liver injury Gut 41(4), 534-540 (1997).
62. *) 0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin. Exp. Allergy 35(3), 339-344 (2005).
63. Dekker JW, Nizankowska E, Schmitz-Schumann M et al.: Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes. Clin. Exp. Allergy 27(5), 574-577 (1997). (Pubitemid 27241657)
64. *0301 as a strong marker in a Korean population. J. Allergy Clin. Immunol. 113(3), 562-564 (2004).
65. Palikhe NS, Kim SH, Park HS: What do we know about the genetics of aspirin intolerance? J. Clin. Pharm. Ther. 33(5), 465-472 (2008). • Focuses on the two major types of aspirin intolerance, aspirin-intolerant asthma and aspirin-intolerant urticaria, their clinical presentation, diagnosis and pathogenesis. Also discussed in detail are the genetic susceptibility markers, including the MHC class II and leukotriene-related genes.
66. Haas N, Toppe E, Henz BM: Microscopic morphology of different types of urticaria. Arch. Dermatol. 134(1), 41-46 (1998). (Pubitemid 28087112)
67. Haas N, Hermes B, Henz BM: Adhesion molecules and cellular infiltrate: histology of urticaria. J. Investig Dermatol. Symp. Proc. 6(2), 137-138 (2001). (Pubitemid 33758588)
68. Haas N, Iwen W, Grabbe J, Uchanska-Ziegler B, Czarnetzki BM: MHC class II antigen expression is increased in different forms of urticaria. Int. Arch. Allergy Immunol. 109(2), 177-182 (1996). (Pubitemid 26029385)
69. Szczeklik A, Nizankowska E, Duplaga M: Natural history of aspirin-induced asthma. Eur. Respir. J. 16(3), 432-436 (2000).
70. Szczeklik A, Stevenson DD: Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J. Allergy Clin. Immunol. 111(5), 913-921 (2003). (Pubitemid 36570845)
71. Choi JH, Kim SH, Cho BY et al.: Association of TNF-α promoter polymorphisms with aspirin-induced urticaria. J. Clin. Pharm. Ther. 34(2), 231-238 (2009).
72. *) 0301. Clin. Exp. Allergy 36(10), 1247-1253 (2006).
73. Kim SH, Yang EM, Lee HN, Cho BY, Ye YM, Park HS: Combined effect of IL-10 and TGF-β1 promoter polymorphisms as a risk factor for aspirin-intolerant asthma and rhinosinusitis. Allergy 64(8), 1221-1225 (2009).
74. Park HJ, Ye YM, Hur GY, Kim SH, Park HS: Association between a TGFβ1 promoter polymorphism and the phenotype of aspirin-intolerant chronic urticaria in a Korean population. J. Clin. Pharm. Ther. 33(6), 691-697 (2008).
75. Quiralte J, Sanchez-Garcia F, Torres MJ et al.: Association of HLA-DR11 with the anaphylactoid reaction caused by nonsteroidal anti-inflammatory drugs. J. Allergy Clin. Immunol. 103(4), 685-689 (1999). (Pubitemid 29295578)
76. Finks SW, Finks AL, Self TH: Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure. South. Med. J. 99(1), 18-22 (2006).
77. Cameron HA, Ramsay LE: Lupus syndrome induced by hydralazine: a common complication with low dose treatment. BMJ (Clin. Res. Ed). 289(6442), 410-412 (1984).
78. Viznerova A, Slavikova Z, Ellard GA: The determination of the acetylator phenotype of tuberculosis patients in Czechoslovakia using sulphadimidine. Tubercle 54(1), 67-71 (1973).
79. Perry HM, Tan EM, Carmody S, Sakamoto A: Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J. Lab. Clin. Med. 76(1), 114-125 (1970).
80. Batchelor JR, Welsh KI, Tinoco RM et al.: Hydralazine-induced systemic lupuserythematosus - influence of HLA-DR and sex on susceptibility. Lancet 1(8178), 1107-1109 (1980).
81. Brand C, Davidson A, Littlejohn G, Ryan P: Hydralazine-induced lupus: no association with HLA-DR4. Lancet 323(8374), 462-462 (1984).
82. Dieterich DT, Robinson PA, Love J, Stern JO: Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin. Infect. Dis. 38, S80-S89 (2004). (Pubitemid 38328169)
83. Havlir D, Cheeseman SH, McLaughlin M et al.: High-dose nevirapine - safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J. Infect. Dis. 171(3), 537-545 (1995).
84. Pollard RB, Robinson P, Dransfield K: Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin. Ther. 20(6), 1071-1092 (1998). (Pubitemid 29058411)
85. Patel SM, Johnson S, Belknap SM, Chan J, Sha BE, Bennett C: Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 35(2), 120-125 (2004). (Pubitemid 38133733)
86. *f0101 and abrogated by low CD4 T-cell counts. AIDS 19(1), 97-99 (2005). (Pubitemid 40111026)
87. Littera R, Carcassi C, Masala A et al.: HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 20(12), 1621-1626 (2006). (Pubitemid 44162404)
88. Gatanaga H, Yazaki H, Tanuma J et al.: HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 21(2), 264-265 (2007). (Pubitemid 46036947)
89. *04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Res. Ther. 6, 22 (2009).
90. *3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet. Genomomics 19(2), 139-146 (2009).
91. *01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 22(4), 540-541 (2008). (Pubitemid 351317299)
92. Padovan E, Mauri-Hellweg D, Pichler WJ, Weltzien HU: T-cell recognition of penicillin G: structural features determining antigenic specificity. Eur. J. Immunol. 26(1), 42-48 (1996). (Pubitemid 26028410)
93. Padovan E, Bauer T, Tongio MM, Kalbacher H, Weltzien HU: Penicilloyl peptides are recognized as T-cell antigenic determinants in penicillin allergy. Eur. J. Immunol. 27(6), 1303-1307 (1997). •• Characterizes T-cell stimulation in T-cell mediated hypersensitivity to aminopenicillins, including work with synthetic, penicilloyl modified peptides, portraying the hapten/prohapten concept as a method of T-cell stimulation. (Pubitemid 27254817)
94. Padovan E: T-cell response in penicillin allergy. Clin. Exp. Allergy 28 (Suppl. 4), 33-36 (1998) (Pubitemid 28429664)
95. Hertl M, Merk HF: Lymphocyte activation in cutaneous drug reactions. J. Invest. Dermatol. 105(1), S95-S98 (1995).
96. Romano A, De Santis A, Romito A et al.: Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. Ann. Allergy. Asthma. Immunol. 80(5), 433-437 (1998). (Pubitemid 28246777)
97. Schmidt KL, Muellereckhardt C: Agranulocytosis, levamisole and HLA-B27. Lancet 2(8028), 85-85 (1977).
98. Wooley PH, Griffin J, Panayi GS, Batchelor JR, Welsh KI, Gibson TJ: HLA-DR antigens and toxic reaction to sodium aurothiomalate and d-penicillamine in patients with rheumatoid arthritis N. Engl. J. Med. 303(6), 300-302 (1980). (Pubitemid 10040017)
99. Roujeau JC, Bracq C, Huyn NT, Chaussalet E, Raffin C, Duedari N: HLA phenotypes and bullous cutaneous reactions to drugs Tissue Antigens 28(4), 251-254 (1986). (Pubitemid 17201461)
100. Roujeau JC, Huynh TN, Bracq C, Guillaume JC, Revuz J, Touraine R: Genetic susceptibility to toxic epidermal necrolysis Arch. Dermatol. 123(9), 1171-1173 (1987). (Pubitemid 17119310)
101. Kindmark A, Jawaid A, Harbron CG et al.: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8(3), 186-195 (2008). (Pubitemid 351712643)
102. Yunis JJ, Corzo D, Salazar M, Lieberman JA, Howard A, Yunis EJ: HLA association in clozapine-induced agranulocytosis Blood 86(3), 1177-1183 (1995).
103. Weiss ST, McLeod HL, Flockhart DA et al.: Creating and evaluating genetic tests predictive of drug response. Nat. Rev. Drug Discov. 7(7), 568-574 (2008).
104. Van Kaer L: Major histocompatibility complex class I-restricted antigen processing and presentation. Tissue Antigens 60(1), 1-9 (2002). • Seminal review of how the MHC-I-restricted antigens are processed and presented to CD8-expressing cytotoxic T lymphocytes. (Pubitemid 35177018)
105. Pohl LR, Satoh H, Christ DD, Kenna JG: The immunologic and metabolic basis of drug hypersensitivities. Annu. Rev. Pharmacol. Toxicol. 28, 367-387 (1988).
106. Naisbitt DJ, Gordon SF, Pirmohamed M et al.: Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br. J. Pharmacol. 133(2), 295-305 (2001). (Pubitemid 32507049)
107. Levine BB, Ovary Z: Studies on the mechanism of the formation of the penicillin antigen. III. The N-(D-α-benzylpenicilloyl) group as an antigenic determinant responsible for hypersensitivity to penicillin G. J. Exp. Med. 114, 875-904 (1961).
108. Pichler WJ, Beeler A, Keller M et al.: Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol. Int. 55(1), 17-25 (2006).
109. Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler WJ: Direct MHC-dependent presentation of the drug sulfamethoxazole to human α β T-cell clones. J. Clin. Invest. 100(1), 136-141 (1997). (Pubitemid 27311251)
110. Zanni MP, von Greyerz S, Schnyder B et al.: HLA-restricted, processing-and metabolismindependent pathway of drug recognition by human α β T lymphocytes. J. Clin. Invest. 102(8), 1591-1598 (1998). (Pubitemid 28492227)
111. Pirmohamed M, Lin K, Chadwick D, Park BK: TNFα promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 56(7), 890-896 (2001). (Pubitemid 32290806)
112. Markel A: Allopurinol-induced DRESS syndrome. Isr. Med. Assoc. J. 7(10), 656-660 (2005). (Pubitemid 41508721)
113. Custodio das Dores SM, Booth SL, Martini LA et al.: Relationship between diet and anticoagulant response to warfarin: a factor ana lysis. Eur. J. Nutr. 46(3), 147-154 (2007).
114. Caffrey MFP, Jams DCO: Human lymphocyte antigen association in ankylosing spondylitis. Nature 242(5393), 121 (1973).
115. Durrani K, Papaliodis GN: The genetics of Adamantiades-Behcet's disease. Semin. Ophthalmol. 23(1), 73-79 (2008). (Pubitemid 351156980)
116. Boisgerault F, Khalil I, Tieng V et al.: Definition of the HLA-A29 peptide ligand motif allows prediction of potential T-cell epitopes from the retinal soluble antigen, a candidate autoantigen in birdshot retinopathy. Proc. Natl Acad. Sci. USA 93(8), 3466-3470 (1996). (Pubitemid 26125643)
117. McCluskey J, Gras S, Bharadwaj M et al.: HLA molecules of the major histocompatibility complex. In: The HLA Complex in Biology and Medicine: A Resource Book. Jaypee Brothers Medical Publishers Ltd, New Delhi, India (2009).
118. Maclaren NK, Riley WJ: Inherited susceptibility to autoimmune Addison's disease is linked to human leukocyte antigens-DR3 and/or DR4, except when associated with Type I autoimmune polyglandular syndrome. J. Clin. Endocrinol. Metab. 62(3), 455-459 (1986).
119. Hendel H, Caillat-Zucman S, Lebuanec H et al.: New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J. Immunol. 162(11), 6942-6946 (1999). (Pubitemid 29309424)
120. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD: Ankylosing spondylitis and HL-A27. Lancet 1(7809), 904-907 (1973).
121. Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M: Close association of HLA-Bw51 with Behcet's disease. Arch. Ophthalmol. 100(9), 1455-1458 (1982). (Pubitemid 12055531)
122. Tabary T, Lehoang P, Betuel H et al.: Susceptibility to birdshot chorioretinopathy is restricted to the HLA-A29.2 subtype. Tissue Antigens 36(4), 177-179 (1990).
123. *02 (DQ2) heterodimer: results from the European genetics cluster on celiac disease. Hum. Immunol. 64(4), 469-477 (2003). (Pubitemid 36373778)
124. Mackay IR: Historical reflections on autoimmune hepatitis. World J. Gastroenterol. 14(21), 3292-3300 (2008).
125. Nyulassy S, Hnilica P, Buc M, Guman M, Hirschova V, Stefanovic J: Subacute (de Quervains) thyroiditis - association with HLA-Bw35 antigen and abnormalities of the complement cystem, immunoglobulins and other serum proteins. J. Clin. Endocrinol. Metab. 45(2), 270-274 (1977). (Pubitemid 8162813)
126. Solheim BG, Albrechtsen D, Thorsby E, Thune P: Strong association between an HLA-Dw3 associated B-cell alloantigen and dermatitis heptiformis. Tissue Antigens 10(2), 114-118 (1977). (Pubitemid 8169150)
127. *07 is protective. J. Clin. Endocrinol. Metab. 84(9), 3182-3186 (1999).
128. *07 in hemochromatosis probands with HFE C282Y homozygosity: frequency disparity in men and women and lack of association with severity of iron overload. Blood Cells. Mol. Dis. 34(1), 38-47 (2005).
129. Price P, Witt C, Allcock R et al.: The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol. Rev. 167, 257-274 (1999). (Pubitemid 29178987)
130. Nejentsev S, Howson JMM, Walker NM et al.: Localization of Type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 450(7171), 887-819 (2007). (Pubitemid 350231332)
131. Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F: Prognostic factors in mesangial IgA glomerulonephritis - an extensive study with univariate and multivariate analyses Am. J. Kidney Dis. 18(1), 12-19 (1991).
132. Berntson L, Damgård M, Andersson-Gäre B et al.: HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis. J. Rheumatol. 35(10), 2055-2061 (2008).
133. Kuttenn F, Couillin P, Girard F et al.: Late-onset adrenal hyperplasia in hirsutism. N. Engl. J. Med. 313(4), 224-231 (1985). (Pubitemid 15068638)
134. Hill AVS, Elvin J, Willis AC et al.: Molecular analysis of the association of HLA-B53 and resistance to severe malaria Nature 360(6403), 434-439 (1992).
135. Degli-Esposti MA, Andreas A, Christiansen FT, Schalke B, Albert E, Dawkins RL: An approach to the localization of the susceptibility genes for generalized myasthenia gravis by mapping recombinant ancestral haplotypes. Immunogenetics 35(6), 355-364 (1992).
136. *0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. Tissue Antigens 51(1), 96-100 (1998). (Pubitemid 28014550)
137. Wucherpfennig KW, Yu B, Bhol K et al.: Structural basis for major
138. *1501 allele confer more severe and faster progression in primary progressive multiple sclerosis patients? HLA in primary progressive multiple sclerosis. J. Neuroimmunol. 214 (1-2), 101-103 (2009).
139. Griffiths CEM, Barker JN: Pathogenesis and clinical features of psoriasis. Lancet 370(9583), 263-271 (2007).
140. Winchester R: Psoriatic arthritis. Dermatol. Clin. 13(4), 779-792 (1995).
141. Ebringer A, Wilson C: HLA molecules, bacteria and autoimmunity. J. Med. Microbiol. 49(4), 305-311 (2000). (Pubitemid 30189463)
142. Hietaharju A, Korpela M, Ilonen J, Frey H: Nervous system disease, immunological features, and HLA phenotype in Sjogran's syndrome Ann. Rheum. Dis. 51(4), 506-509 (1992).
143. Graham RR, Ortmann W, Rodine P et al.: Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur. J. Hum. Genet. 15(8), 823-830 (2007). (Pubitemid 47109040)
144. Flores-Domínguez C, Hernández-Pacheco G, Zúñiga J et al.: Alleles of the major histocompatibility system associated with susceptibility to the development of Takayasu's arteritis. Gac. Med. Mex. 138(2), 177-183 (2002). (Pubitemid 34453920)
145. Posthuma EF, Falkenburg JH, Apperley JF et al.: HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The chronic leukemia working party of the EBMT Blood 93(11), 3863-3865 (1999).
146. *5703-peptide complexes and identification of related HLAs potentially associated with long-term nonprogression. J. Immunol. 175(4), 2459-2468 (2005). (Pubitemid 41113856)
147. Bolin DR, Swain AL, Sarabu R et al.: Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and x-ray crystal structures. J. Med. Chem. 43(11), 2135-2148 (2000). (Pubitemid 30354538)